The Patent Finder
AT

Atossa Therapeutics, Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

10 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Aug 2030. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Aug 2030
Next term end
4
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 20, 2026
    The maintenance fee for Methods for Making and Using Endoxifen (US 11,680,036) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
  • 1 fee due Sep 29, 2027
    The maintenance fee for Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof (US 9,295,658) comes due Sep 29, 2027. Unpaid by Mar 29, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 10 of 10

PatentTitleStatusExpiresConfidence
US 9,295,658Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof
In force
 · High confidence
In forceHigh confidence
US 11,572,334Methods for Making and Using Endoxifen
In force
 · High confidence
In forceHigh confidence
US 11,680,036Methods for Making and Using Endoxifen
In force
 · High confidence
In forceHigh confidence
US 12,071,391Methods for Making and Using Endoxifen
In force
 · Medium confidence
In forceMedium confidence
US 12,275,684Methods for Making and Using Endoxifen
In force
 · Medium confidence
In forceMedium confidence
US 12,281,056Methods for Making and Using Endoxifen
In force
 · High confidence
In forceHigh confidence
US 12,479,790Methods for Making and Using Endoxifen
In force
 · High confidence
In forceHigh confidence
US 11,261,151Methods for Making and Using Endoxifen
In force
 · High confidence
In forceHigh confidence
US 12,201,591Sustained Release Compositions of Endoxifen
In force
 · High confidence
In forceHigh confidence
US 12,576,103Heparin and N-Acetylcysteine for the Treatment of Lung Injury
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 10: 33 patents ended · 24 applications pending · 32 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited